Hypertension Diagnostics Stock Revenue
Hypertension Diagnostics fundamentals help investors to digest information that contributes to Hypertension Diagnostics' financial success or failures. It also enables traders to predict the movement of Hypertension Pink Sheet. The fundamental analysis module provides a way to measure Hypertension Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hypertension Diagnostics pink sheet.
Hypertension |
Hypertension Diagnostics Company Revenue Analysis
Hypertension Diagnostics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Hypertension Diagnostics Revenue | 3.79 M |
Most of Hypertension Diagnostics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Hypertension Diagnostics reported 3.79 M of revenue. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 99.96% higher than that of the company.
Hypertension Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in revenue category among its peers.
Hypertension Fundamentals
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| Gross Profit | 954.47 K | ||||
| EBITDA | 72.29 K | ||||
| Net Income | (125.39 K) | ||||
| Cash And Equivalents | 5.66 K | ||||
| Total Debt | 4.69 M | ||||
| Current Ratio | 0.52 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (389.28 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 730.42 K | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (30.68 M) | ||||
| Working Capital | (857 K) | ||||
| Current Asset | 277 K | ||||
| Current Liabilities | 1.13 M | ||||
| Z Score | -31.6 | ||||
| Net Asset | 1.28 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |